Parthenon Entered into a Multi-Year Non-Exclusive License and Supply Agreement with ImaginAb to Advance Anti-Cancer Therapies
Shots:
- The collaboration enables Parthenon to use ImaginAb’s CD8 ImmunoPET imaging technology to initiate a P-I trial of PRTH-101 with an expected initiation in 2023
- Parthenon will get the clinical doses of CD8 ImmunoPET technology in the clinical development of PRTH-101 at clinical trial sites across the US & will identify the CD8 status in a P-I dose escalation trial of PRTH-101 as monothx. and in combination with anti-PD(L)1 therapy
- For the successful integration of its CD8 ImmunoPET technology into Parthenon Therapeutics' clinical trials, ImaginAb will receive the payments for manufacturing doses and ongoing technical, clinical, and regulatory support
ef: PRNewswire | Image: Parthenon
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
